Diana Campelo Delgado,  —

Articles by

Catabasis Using $110M Investment to Advance QLS-215 Therapy

Catabasis Pharmaceuticals will use a $110 million private investment to complete preclinical and early clinical studies evaluating QLS-215, its investigational kallikrein-inhibitor therapy  for hereditary angioedema (HAE). QLS-215 became Catabasis’ lead product after it acquired the original developer, Quellis Biosciences, in January 2021. Now, the company plans to…